

Email: [jlotz@lotzandco.com](mailto:jlotz@lotzandco.com)  
File: 00131-001

October 23, 2017

VIA SEDAR

British Columbia Securities Commission  
P.O. Box 10142, Pacific Centre  
701 West Georgia Street  
Vancouver, British Columbia, V7Y 1L2

Attention: Financial Reporting Department

Dear Sirs/Mesdames:

**Re: PreveCeutical Medical Inc. (the "Company")  
Financial Statements and MD&A for the Period Ended June 30, 2017  
SEDAR Project No. 02671454**

---


We write on behalf of the Company and in connection with a continuous disclosure review by the British Columbia Securities Commission (the "Commission") related to the Company's interim consolidated financial statements for the period ended June 30, 2017 (the "Financial Statements"). The Financial Statements have been amended and restated and, accordingly, the following documents are being re-filed on SEDAR as follows:

1. amended and restated interim consolidated financial statements (Project No. 02671454);
2. amended and restated management's discussion and analysis (Project No. 02671464);  
and
3. CEO and CFO certifications (Project No. 02671470).

As a result of the Commission's review, the disclosure in the Financial Statements has been updated to fully account for the full listing cost and non-cash consideration provided as part of a reverse-takeover transaction completed by the Company on June 30, 2017.

Yours truly,

LOTZ & COMPANY



Jonathan C. Lotz

JCL/csc  
Encls.

cc: PreveCeutical Medical Inc.  
Attention: Shabira Rajan, CFO (via email; w/o enclosures)